Clinical Trials Browser

Phase 2 × Glioblastoma × Ferrosoferric Oxide × Clear all

NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2 Terminated

52 enrolled 15 charts

Glioblastoma